{"schema_version":"secwatch.filing_event.v1","accession":"0001607062-22-000586","form_type":"8-K","ticker":"RGBP","cik":"0001589150","company_name":"Regen BioPharma Inc","filed_at":"2022-09-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.275724+00:00","generated_at":"2026-06-23T08:31:57.721589+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Regen BioPharma files patent on RNA/DNA dual checkpoint-gene silencing immunotherapy","bullets":["Filed provisional patent 'Dual Checkpoint Inhibitor Aptamer Based Therapeutics' targeting NR2F6 and Survivin gene silencing combined with PD-1 checkpoint inhibition.","Company claims it is the first combination of immunotherapy and gene silencing in a single drug.","Technology uses aptamers (short DNA/RNA) to deliver gene-silencing sequences while inhibiting traditional immune checkpoints like PD-1.","CEO David Koos believes platform will yield numerous potent therapeutic candidates."],"urls":{"canonical":"https://secwatch.observer/filing/0001607062-22-000586","json":"https://secwatch.observer/filing/0001607062-22-000586.json","markdown":"https://secwatch.observer/filing/0001607062-22-000586.md","text":"https://secwatch.observer/filing/0001607062-22-000586.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589150/000160706222000586/0001607062-22-000586-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589150/000160706222000586/rgbp091922form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T08:31:57.721589+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}